Drugs / GI heptapeptide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01630798 | Jul 2012 → Sep 2013 | Barrett esophagus | University of Michigan | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01391208 Comparator | Feb 2011 → Jun 2012 | Barrett esophagus, esophageal adenocarcinoma | University of Michigan | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GI heptapeptide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01391208 ↗ |
| Modality | Peptide | “topically-administered 7-amino acid peptide” NCT01391208 ↗ |
| Route | Topical | “The endoscopist will spray the reconstituted 5-FITC-labeled peptide onto the esophageal mucosa through a catheter in the endoscope.” NCT01391208 ↗ |